1Bombardier S, Vitali C, Capoint, et al. Activity critena in systemic lupus erythematosus[J]. Clin Exp Rheum, 1994, 12(11):45.
2Van Der Zee JM, Siegert CEH, DE reede TA, et al. Characterization -of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE) [J]. Clin Exp Immunol, 1991, 84(2):238.
3Hashemi S, Smith CD, Izaguirre CA. Anti-endothelial cell antibodies:detection and characterization using a celluar enzyme-linked immunosorbent assay[J] .J Lab Clin Med, 1987, 109(4):434-440.
2Inoh M,Tokuda M,Kiuchi H，et al.Evaluating systemic lupus erythematosus diseaseactivity using molecular markers of hemostasis.Arthritis Rheum,1996 Feb,39(2)∶287-291.
3Salazar paramo M, Garcia de la Torre l, Fritzler Mj,et al.Antibodies tofibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus areassociated with Raynaud's phenomenon and thrombosis. Lupus, 1996 Aug, 5(4)∶275-278.
4Doria A, Ghirardello A, Boscaro M,et al.Fibrinolysis and coagulation abnormalitiesin systemic lupus erythematousus.Relationship with Raynaud's phenomenon, diseaseactivity,inflammatory indices,anticardiolipin and corticosteroid therapy.Rheumatolint,1995,14(5)∶207-211.
（收稿：1999-07-06 修回：1999-10-11）
5Liang M H,Socher S A Larson M G,et al.Reliability and validity of six systems for the clinical assessment of disease activity insystemic lupus erythematosus. Arthritis Rheum,1989,32(1)∶1107-110.
6Schorer AE. Discordant effects on eicosanoid and fibrin degradati on products intwo murine models of antiphospholipid antibody.Thromb Res,1997 Feb, 85(4)∶295-304.
7Atsumi T,Khamashta MA,Andujar C, et al. Elevated jplasma lipoprotein(a)level anits association with impaired fibrinolysis in patients with antiphospholipid syndrome.JRhematol,1998 Jan,25(1)∶69-70.
